Inova launches next-gen EIA/IFA processor, 3/18
March 2018—Inova Diagnostics announced the launch of its Quanta-Lyser 3000, a fully automated enzyme-linked immunoassay and immunofluorescence assay processor for use in clinical laboratories.
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
cfDNA reference standard for EGFR mutations, 3/18
March 2018—Horizon Discovery launched its EGFR Multiplex cfDNA Reference Standard. The cell line-derived EGFR multiplex cell-free DNA reference standard allows laboratories and assay developers to optimize, validate, and routinely monitor performance of polymerase chain reaction–based tests, next-generation sequencing, and other novel assays designed to detect EGFR mutations from cfDNA.
Confocal laser scanning microscope, 3/18
March 2018—Olympus announced the availability of the FV3000 confocal laser scanning microscope in two upright models designed for in vitro and in vivo experiments.
Thermo Fisher unveils line of NGS instruments, 3/18
March 2018—Thermo Fisher Scientific announced the Ion GeneStudio S5 Series, a line of benchtop next-generation sequencing instruments that provides flexibility and scalability enabled by five Ion S5 chips, including the new Ion 550 chip, on a single platform. Research applications include cancer, inherited disease, and microbial and infectious diseases.
FDA-cleared Access AMH immunoassay, 3/18
March 2018—Beckman Coulter Diagnostics announced FDA clearance of its automated Access AMH immunoassay for in vitro diagnostic use. This test aids health care providers in the assessment of a woman’s ovarian reserve and helps guide the clinical management of women struggling with infertility or planning to become pregnant later in life.
Genoptix to acquire Rosetta Genomics, 3/18
March 2018—Genoptix and Rosetta Genomics announced they have entered into a definitive merger agreement under which Genoptix will acquire all of the outstanding shares of Rosetta Genomics for a total gross purchase price of $10 million.
Recombinant allergens, 3/18
March 2018—Meridian Life Science introduced its recombinant allergens for the development of serum-based IgE-mediated allergen diagnostic assays.
Updated CLSI Supplement M100, 3/18
March 2018—The Clinical and Laboratory Standards Institute published its annually updated antimicrobial susceptibility testing supplement, “M100: Performance Standards for Antimicrobial Susceptibility Testing, 28th ed.,” as well as its associated methodology standards, “M02: Performance Standards for Antimicrobial Disk Susceptibility Tests, 13th ed.” and “M07: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 11th ed.” M100 is available packaged with either M02 or M07 or the three documents are available packaged together.
Ortho Vitros ALTV Slides, 3/18
March 2018—Ortho Clinical Diagnostics launched its Vitros ALTV Slides for the measurement of alanine aminotransferase, a key liver function enzyme found in serum and plasma, using dry slide technology.
Bordetella pertussis antigens for IVD use
March 2018—Binding Site’s Immunologicals Group has added three Bordetella pertussis (VZV) antigens to its offering of products for in vitro diagnostic manufacturing and research applications. The Bordetella pertussis FHA, Bordetella pertussis Toxin PT, and Bordetella pertussis Whole-Cell Antigens have been designed for use as integral components within solid phase enzyme immunoassay test procedures.